

HHS Public Access

Author manuscript *Sleep Sci Pract.* Author manuscript; available in PMC 2019 September 16.

Published in final edited form as: *Sleep Sci Pract.* 2018 ; 2: . doi:10.1186/s41606-018-0031-1.

Do the Morningness-Eveningness Questionnaire and Munich ChronoType Questionnaire Change After Morning Light Treatment?

Helen J. Burgess, Ph.D.¹, Fumitaka Kikyo, B.A.¹, Zerbrina Valdespino-Hayden, B.A.², Muneer Rizvydeen, B.A.¹, Momoko Kimura, B.S.¹, Mark H. Pollack, M.D.², Stevan E. Hobfoll, Ph.D.¹, Kumar B. Rajan, Ph.D.³, Alyson K. Zalta^{1,2}, and John W. Burns, Ph.D.¹

Fumitaka Kikyo: Fumitaka_Kikyo@rush.edu; Zerbrina Valdespino-Hayden: valdespinoz1@mail.montclair.edu; Muneer Rizvydeen: Muneer_Rizvydeen@rush.edu; Momoko Kimura: Momoko_Kimura@rush.edu; Mark H. Pollack: Mark_Pollack@rush.edu; Stevan E. Hobfoll: Stevan_Hobfoll@rush.edu; Kumar B. Rajan: kbrajan@ucdavis.edu; Alyson K. Zalta: Alyson_Zalta@rush.edu; John W. Burns: John_Burns@rush.edu

¹Department of Behavioral Sciences, Rush University Medical Center, Chicago IL.

²Department of Psychiatry, Rush University Medical Center, Chicago IL.

³Department of Internal Medicine, Rush University Medical Center, Chicago IL.

Abstract

The Morningness-Eveningness Questionnaire (MEQ) and Munich ChronoType Questionnaire (MCTQ) are sometimes used to estimate circadian timing. However, it remains unclear if they can reflect a change in circadian timing after a light treatment. In this study, 31 participants (25–68 years) completed both questionnaires before and after a 13–28 day morning light treatment. The dim light melatonin onset (DLMO), a physiological marker of circadian timing, was also assessed in a subsample of 16 participants. The DLMO phase advanced on average by 47 minutes (p<0.001). The MEQ score increased by 1.8 points (p=0.046). The MSFsc measure derived from the MCTQ advanced by 8.7 minutes (p=0.17). The shift towards morningness observed in both questionnaires correlated with the phase advance observed in the DLMO (MEQ r=-0.46, p=0.036; MSFsc r=0.81, p<0.001). Results suggest that these circadian questionnaires can change in response to a light treatment, indicating they can reflect underlying changes in circadian timing.

Abstract

Trial registration:Clinicaltrials.gov NCT02373189 retrospectively registered 2/26/15; NCT03513848 retrospectively registered 5/2/18.

Correspondence to: Helen J. Burgess, Ph.D., Biological Rhythms Research Laboratory, Suite 425, 1645 West Jackson Blvd., Chicago IL 60612, phone 312 563 4785, fax 312 563 4900, Helen_J_Burgess@rush.edu.

DECLARATIONS

Dr. Burgess is a consultant for Natrol, LLC. Dr. Pollack reports personal fees from Aptinyx, Bracket Global, Palo Alto Health Sciences, grants from Janssen, outside the submitted work. In addition, Dr. Pollack has a patent SIGHA, SAFER interviews with royalties paid and Equity in Argus, Doyen Medical, Mensante Corporation, Mindsite, Targia Pharmaceuticals. All other authors report no conflicts of interest.

Keywords

circadian; human; light; melatonin; sleep

Introduction

The dim light melatonin onset (DLMO) is the most reliable measure of central circadian timing in humans (Lewy et al. 1999, Klerman et al. 2002). The onset of the secretion of melatonin, which is tightly controlled by the central circadian clock (suprachiasmatic nucleus, SCN) (Moore 1996), typically begins 2–3 hours before habitual sleep onset (Burgess and Fogg 2008). The melatonin rhythm must be measured in dim light, as it is suppressed by light (Lewy et al. 1980). The DLMO can usually be obtained from saliva samples, collected every half-hour or hour, in the 6 hour window before habitual sleep onset (Burgess and Fogg 2008). However, there are significant disadvantages in measuring the DLMO: it requires staff to assist in the collection and processing of samples, significant participant effort, and the melatonin assay can be costly (~\$14 per sample). For these reasons, there remains considerable interest in estimating circadian timing with questionnaires.

Two such questionnaires include the Morningness-Eveningness Ouestionnaire (MEO) (Horne et al. 1976), and the Munich ChronoType Questionnaire (MCTQ) (Roenneberg et al. 2003). As we reviewed previously (Kantermann et al. 2015), the MEQ includes 19 questions that ask people to consider their "feeling best" rhythms and indicate preferred clock time blocks for sleep and engagement in various hypothetical activities (e.g. physical exercise, tests, work), in addition to assessing morning alertness, morning appetite, evening tiredness and alarm clock dependency. MEQ scores can range from 16 to 86, with lower scores indicating eveningness or later circadian timing, and higher scores indicating morningness or earlier circadian timing. By contrast, the MCTQ focuses primarily on sleep timing and via 14 questions, assesses the regularity of one's work schedule, number of workdays per week, sleep timing on workdays and work-free days, and alarm clock use on workdays and workfree days. Circadian timing is estimated as the midpoint of sleep on work-free days minus half of the difference between sleep duration on work-free days and average sleep duration of the week to control for sleep debt (midpoint of sleep on work-free days, sleep corrected, referred to from here on as MSFsc). Importantly, the MSFsc should only be considered valid when individuals report not using an alarm clock on work-free days (Roenneberg et al. 2012). We and others have reported that the estimates of circadian timing generated from these questionnaires, do indeed correlate significantly with the DLMO (MEQ and DLMO rs = -0.40 to -0.70; MSFsc and DLMO rs = 0.54 to 0.68; (Kitamura et al. 2014, Kantermann et al. 2015). A related, but to date unanswered, question is whether these questionnaires are sensitive enough to reflect an underlying change in circadian timing following a light treatment. If they do, this would further support their use as potential estimators of circadian timing when direct measurement of the DLMO is not feasible. Thus, the objective of this study was to examine these circadian questionnaires before and after a bright light treatment.

Materials and Methods

Our sample consisted of 31 participants (23 males, 8 females, mean age 45.9 ± 13.7 years, mean BMI $30.3 \pm 6.0 \text{ kg/m}^2$, 45% Non-Hispanic African American, 32% Non-Hispanic White, 19% Hispanic White, 3% other) who were recruited from internet advertising (e.g. craigslist.com). The majority was not working (68% not working, 26% part-time workers, 6% full-time workers), none had engaged in shift work in at least the past month, and all passed a urine drug test and alcohol breathalyzer test. The sample was derived from two separate clinical trials that tested the mood altering effects of a self-administered morning bright light treatment administered at home for 13-28 days. In both studies, the 1 hour light treatment was scheduled to start each morning at the subject's average wake time (derived from a baseline week of wrist actigraphy collected just prior to the start of the light treatment), or up to 1 hour earlier to accommodate morning social responsibilities (e.g. work, child care). In the first trial, 23 U.S. military veterans with chronic low back pain received morning bright light from two broad-spectrum white light boxes that research staff set up in their homes $(33 \times 18 \times 55 \text{ cm}, \text{EnergyLight HF3318/60}, \text{Philips, Inc, generated})$ >3,000 lux at subjects' eyes). The light treatment was scheduled for 13 consecutive mornings (NCT02373189 on clinicaltrials.gov). Light readings from photosensors attached to the light boxes were checked against light readings on each subject's wrist monitor (Actiwatch Spectrum, Philips, Inc) to monitor adherence to the light treatment. In the second trial, 8 subjects with probable post-traumatic stress disorder (Post-Traumatic Stress Disorder Checklist for DSM-5 score >33, (Weathers et al. 2013, Bovin et al. 2016)) received morning light from a wearable light device, the Re-timer ($20 \times 14 \times 5.5$ cm, Re-time, Inc, Australia, generated \sim 500 lux at subjects' eves, with peak wavelength of \sim 500 nm). The Re-timer was individually adjusted to each subject to optimize the light treatment, which was scheduled for 28 consecutive mornings (NCT03513848 on clinicaltrials.gov). Light and activity readings from a monitor (Actiwatch Spectrum, Philips, Inc) attached to the inside of the Retimer were used to monitor adherence to the light treatment. All subjects included in this report received the morning light treatment on at least 80% of the assigned mornings.

The MEQ and MCTQ were measured at the end of the baseline week, which was also the day before the start of the light treatment. They were then re-measured on the day of the last light treatment, after the light treatment had concluded. In the veteran trial, a validated home saliva collection kit (Burgess et al. 2015, Burgess et al. 2016) was used to assess the dim light melatonin onset (DLMO) at the same pre and post-treatment time points. Saliva samples were collected every half hour for 6 hours in dim light (<50 lux), starting 6 hours before average sleep onset time. All subjects refrained from caffeine and alcohol in at least the 24 hours before saliva collection, and refrained from non-steroidal anti-inflammatory drugs for at least 72 hours before saliva collection. No participants were taking beta-blockers or exogenous melatonin. Melatonin levels were derived from the saliva samples by Solidphase Inc (Portland, ME), with a direct radioimmunoassay using standard Buhlmann kits with assay sensitivity of 0.5 pg/ml, intra and interassay CV <7.5% at 3 pg/ml. The DLMO was calculated as the clock time (with linear interpolation) when the melatonin concentration exceeded the mean of 3 low consecutive daytime values plus twice the standard deviation of these points (Voultsios et al. 1997). This low threshold more closely

Burgess et al.

tracks the initial rise of melatonin, when the SCN triggers the release of melatonin from the pineal gland (Molina et al. 2011). The DLMOs for seven veterans were not valid due to low levels of melatonin (< 5pg/ml) or erratic melatonin profiles. The DLMO was not assessed in the PTSD trial. The Rush University Medical Center Institutional Review Board approved both study protocols, which followed the principles of the Declaration of Helsinki. All subjects gave written informed consent prior to participation. The changes in DLMO, MEQ and MSFsc (derived from the MCTQ) were analyzed with a paired samples t-test. As

morning light is well recognized to cause circadian phase advances, an increase in morningness was predicted, and a one-tailed p-value of <0.05 was used to determine statistical significance.

Results

The variables were normally distributed. The changes in the DLMO, MEQ score and MSFsc from pre- to post- light treatment are shown in Figure 1. On average, the DLMO significantly phase advanced by 47 minutes (p<0.001, n=16, d=1.49). The MEQ score significantly increased by 1.8 points (p=0.046, n=31, d=0.32), reflecting more morningness after the morning light treatment. The MSFsc advanced by 8.7 minutes, but this was not statistically significant (p=0.17, n=31, d=0.17). Nine subjects reported using alarm clocks on their non-work days. With those subjects removed the advance in MSFsc increased to 14.4 minutes, but this change was still not significant (p=0.12, n=22, d=0.25). Overall, the phase advance in the DLMO correlated with an increase in morningness on both questionnaires (MEQ r=-0.46, p=0.036; MSFsc r=0.81, p<0.001, n=16).

Discussion

These results indicate that the MEQ and MCTQ questionnaires can reflect an increase in morningness following a morning light treatment. The MEQ score increased significantly, reflecting more morningness, and also correlated with the phase advance in the DLMO. The MSFsc derived from the MCTQ did not significantly change with the light treatment, but the increase in morningness did correlate significantly with the degree of circadian phase advance observed in the DLMO. Thus these results further support the use of these circadian questionnaires as potential estimators of circadian timing when direct measurement of the DLMO is not feasible. Contrary to other sleep questionnaires, the MEQ and MCTQ (at least the earlier version we used in this study) do not have any time frame in their instructions for completion, such as "in the past week" which is used in the Insomnia Severity Index (Bastien et al. 2001) and "during the past month only" which is used in the Pittsburgh Sleep Quality Index (Buysse et al. 1989). This lack of time reference may have reduced the ability to detect differences in the MEQ score and MSFsc, with assessments only 2-4 weeks apart. The greater sensitivity of the MEQ to the morning light treatment may be due to the questions in the MEQ assessing a broader range of activities beyond sleep, including for example people's "feeling best" rhythms and preferred clock times for engagement in various hypothetical activities (e.g. physical exercise, tests, work), in addition to assessing morning alertness, morning appetite, evening tiredness and alarm clock dependency. By contrast, the MCTQ focuses primarily on sleep timing and alarm clock use, and responses may be more constrained by perceived societal norms surrounding usual sleep times.

Burgess et al.

Additionally, even though the majority of our sample was not working, almost a third of subjects reported using an alarm clock on their work-free days, which may reflect other nonwork social responsibilities. It remains unclear if these subjects were reporting the setting of an alarm on these days, or the actual waking to an alarm clock on those days. Further, use of an alarm clock on work-free days technically invalidates the MSFsc (Roenneberg et al. 2012), indicating the higher potential for missing data when using the MCTQ than when using the MEQ.

There are several limitations to our study. We were not able to assess DLMO in all subjects, and therefore cannot verify a significant circadian phase advance occurred in the entire sample. Nonetheless, the subsample of 16 subjects revealed a statistically significant phase advance of \sim 50 minutes in response to the morning bright light, which is remarkably consistent with the phase advance seen in the phase response curve to 1 hour of light, when administered at average wake time (~14 hours after the DLMO, Figure 3 in (St Hilaire et al. 2012)). Additionally, the Re-timer has been shown to elicit phase shifts in the DLMO (Lovato et al. 2016). Given that objectively measured adherence to the light treatment in both trials was reasonable, it is likely that on average the entire sample phase advanced in response to the morning light treatment. Indeed the increase of ~2 points in the MEQ observed in the full sample, was similar to that observed in the subsample in which the DLMO was measured. We also note that we have no control group, and thus no measure of the natural fluctuations in these circadian questionnaires over time. We also recognize that our sample size was small, and therefore our analyses were underpowered. We encourage other researchers assessing the circadian effects of light treatment to consider administering these circadian questionnaires both before and after a light treatment to further explore the sensitivity of these questionnaires in larger samples. To our knowledge this is rarely done in light treatment studies. Future work should also examine these relationships in larger nonclinical samples (Di Milia et al. 2013), as our sample is not necessarily representative of the general population and was largely male. It would also be interesting to determine if circadian phase shifts due to other non-photic stimuli, such as exogenous melatonin, could also significantly shift the scores derived from these circadian questionnaires.

ACKNOWLEDGMENTS

We thank Karyna Bravo, Morgan Corich, Joshua Dein, Aahad Kahn, Catherine Keefner, Mary Kennedy, Athanasios Kondilis, Othon Nunez-Montelongo, Daria Orlowska, Philip Sanchez, Monica Thomas, Marie Vallido, Amanda Vatinno, and Denise Zou for their assistance with data collection. Research reported in this publication was supported by the National Center for Complementary and Integrative Health of the National Institutes of Health under Award Number R34AT008347, and by internal funds provided by the Department of Psychiatry at Rush University Medical Center. Alyson Zalta's contribution was supported by a training grant from the National Institute of Mental Health (K23 MH103394). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

List of Abbreviations

BMI	Body mass index
DLMO	Dim light melatonin onset
MSFsc	Midpoint of sleep on work-free days sleep corrected

MEQ	Morningness-Eveningness Questionnaire
MCTQ	Munich ChronoType Questionnaire
PTSD	Post-traumatic stress disorder
SCN	Suprachiasmatic nucleus

REFERENCES

- Bastien CH, Vallieres A, Morin CM. 2001 Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2(4):297–307. [PubMed: 11438246]
- Bovin MJ, Marx BP, Weathers FW, Gallagher MW, Rodriguez P, Schnurr PP, Keane TM. 2016 Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5) in veterans. Psychol Assess. 28(11):1379–1391. [PubMed: 26653052]
- Burgess HJ, Fogg LF. 2008 Individual differences in the amount and timing of salivary melatonin secretion. PLoS One. 3(8):e3055. [PubMed: 18725972]
- Burgess HJ, Park M, Wyatt JK, Fogg LF. 2016 Home dim light melatonin onsets with measures of compliance in delayed sleep phase disorder. J Sleep Res. 25(3):314–317. [PubMed: 26847016]
- Burgess HJ, Wyatt JK, Park M, Fogg LF. 2015 Home circadian phase assessments with measures of compliance yield accurate dim light melatonin onsets. Sleep. 38(6):889–897. [PubMed: 25409110]
- Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. 1989 The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res. 28:193–213. [PubMed: 2748771]
- Di Milia L, Adan A, Natale V, Randler C. 2013 Reviewing the psychometric properties of contemporary circadian typology measures. Chronobiol Int. 30(10):1261–71. [PubMed: 24001393]
- Horne J, Ostberg O. 1976 A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol. 4:97–110. [PubMed: 1027738]
- Kantermann T, Sung H, Burgess HJ. 2015 Comparing the Morningness-Eveningness Questionnaire and Munich ChronoType Questionnaire to the dim light melatonin onset. J Biol Rhythms. 30(5): 449–453. [PubMed: 26243627]
- Kitamura S, Hida A, Aritake S, Higuchi S, Enomoto M, Kato M, Vetter C, Roenneberg T, Mishima K. 2014 Validity of the Japanese version of the Munich ChronoType Questionnaire. Chronobiol Int. 31(7):845–850. [PubMed: 24824747]
- Klerman EB, Gershengorn HB, Duffy JF, Kronauer RE. 2002 Comparisons of the variability of three markers of the human circadian pacemaker. J Biol Rhythms. 17(2):181–193. [PubMed: 12002165]
- Lewy AJ, Cutler NL, Sack RL. 1999 The endogenous melatonin profile as a marker of circadian phase position. J Biol Rhythms. 14(3):227–236. [PubMed: 10452335]
- Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP. 1980 Light suppresses melatonin secretion in humans. Science. 210(4475):1267–1269. [PubMed: 7434030]
- Lovato N, Lack L. 2016 Circadian phase delay using the newly developed re-timer portable light device. Sleep Biol Rhythms. 14:157–164.
- Molina TA, Burgess HJ. 2011 Calculating the dim light melatonin onset: the impact of threshold and sampling rate. Chronobiol Int. 28(8):714–718. [PubMed: 21823817]
- Moore RY. 1996 Neural control of the pineal gland. Behavioral Brain Research. 73:125–130.
- Roenneberg T, Allebrandt KV, Merrow M, Vetter C. 2012 Social jetlag and obesity. Curr Biol. 22(10): 939–943. [PubMed: 22578422]
- Roenneberg T, Wirz-Justice A, Merrow M. 2003 Life between clocks: daily temporal patterns of human chronotypes. J Biol Rhythms. 18(1):80–90. [PubMed: 12568247]
- St Hilaire MA, Gooley JJ, Khalsa SB, Kronauer RE, Czeisler CA, Lockley SW. 2012 Human phase response curve to a 1h pulse of bright white light. J Physiol. 590(Pt 13):3035–3045. [PubMed: 22547633]

- Voultsios A, Kennaway DJ, Dawson D. 1997 Salivary melatonin as a circadian phase marker: validation and comparison to plasma melatonin. J Biol Rhythms. 12(5):457–466. [PubMed: 9376644]
- Weathers FW, Litz BT, Keane TM, Palmieri PA, Marx BP, Schnurr PP. 2013 The PTSD Checklist for DSM-5 (PCL-5). Scale available from the National Center for PTSD at www.ptsd.va.gov.

Burgess et al.

Author Manuscript




Figure 1.

The changes in MSFsc, MEQ score, and DLMO observed in each individual subject before and after a 13 or 28 day morning light treatment. The results for an individual subject are connected by a line. The mean and standard deviation at each time point is also shown.